Foghorn Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Foghorn Therapeutics Inc (FHTX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Foghorn Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 37M vs 108,388M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+75.0% annualized vs trailing 12 months), vs accelerating (+4.2%) for its tracked peer group.
- Growth: Foghorn Therapeutics Inc generated 112.7% revenue growth year over year in Q2 2026, vs 11.8% for its competitors combined.
- Profitability: Its -44.7% net margin compares with 19.6% for the peer group.
- Scale: Foghorn Therapeutics Inc ranks #265 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Foghorn Therapeutics Inc accounted for 0.1% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.35M compares with $1.09M for the peer group (0.3x).
- Structure: Foghorn Therapeutics Inc operates in the following segments: The.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
FHTX Sales vs. its Competitors, Q2 2026
Foghorn Therapeutics Inc reported revenue growth of 112.68 % year on year in Q2 2026, above its competitors' combined revenue growth of 11.79 %.
With a net margin of -44.74 %, Foghorn Therapeutics Inc reported lower profitability than its competitors (19.59 %).
Foghorn Therapeutics Inc generated 0.06 % of the combined sales of its peer group, up from 0.03 % a year earlier.
API endpoints for this dataset
Foghorn Therapeutics Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Foghorn Therapeutics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Foghorn Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Foghorn Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (4) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Foghorn Therapeutics Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 112.7% for Foghorn Therapeutics Inc. Foghorn Therapeutics Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Foghorn Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Foghorn Therapeutics Inc | - | Yes | Yes | Yes |
| Competitors combined (45) | ||||
| High-Confidence Competitors (4) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
FHTX Stock Performance relative to its Competitors
FHTX Stock Performance relative to High-Confidence Competitors
FHTX Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 3 | Prelude Therapeutics Inc | 282.9% | Outperformed |
| 4 | Enliven Therapeutics Inc | 282.9% | Outperformed |
| 5 | Kymera Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Foghorn Therapeutics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Foghorn Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Foghorn Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Foghorn Therapeutics Inc |
132.08 | 36.74 |
 Abbvie Inc |
516,201.32 | 66,014.00 |
 Novartis Ag |
317,785.25 | 56,674.00 |
 Amgen Inc |
250,468.48 | 38,095.00 |
 Hutchmed china Limited |
13,233.03 | 548.51 |
 Kymera Therapeutics Inc |
13,185.81 | 105.00 |
| SUBTOTAL | 1,176,352.95 | 166,361.04 |
Sign in to see all competitors of Foghorn Therapeutics Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Foghorn Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Foghorn Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Foghorn Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Kymera Therapeutics Inc | Company report | 85% |
| Arvinas Inc | Company report | 85% |
| C4 Therapeutics Inc | Company report | 85% |
| Nurix Therapeutics Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Prelude Therapeutics Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Foghorn Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Foghorn Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Foghorn Therapeutics Inc | The 100.00 % |
| Amgen Inc | Reportable 100.00 % |
| Hutchmed china Limited | Other Ventures segment 47.94 % |
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Blueprint Medicines Corporation | Single Reportable Segment 100.00 % |
| Rhythm Pharmaceuticals Inc | Single Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Foghorn Therapeutics Inc .
Foghorn Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Foghorn Therapeutics Inc | 132 | 346,594 | -609,236 |
| Abbvie Inc | 516,201 | 1,158,140 | 181,509 |
| Novartis Ag | 317,785 | 752,973 | 185,566 |
| Amgen Inc | 250,468 | 2,930,385 | 672,538 |
| Hutchmed china Limited | 13,233 | 703,221 | 586,836 |
| Kymera Therapeutics Inc | 13,186 | 441,176 | -1,468,172 |
| PEERS TOTAL | 1,176,221 | 1,089,023 | 205,294 |
Sign in to see all peers for Foghorn Therapeutics Inc .
Foghorn Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Hutchmed china Limited | CN 74.28 % |
| Iovance Biotherapeutics inc | US 98.66 % |
| Xoma Royalty Corporation | CH 54.36 % |
| Adc Therapeutics Sa | United States 96.08 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Foghorn Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Foghorn Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Foghorn Therapeutics Inc ranks #265 of 495 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 875, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 20.69 % |
| 2 | Johnson and Johnson | 674,004 | 11.53 % |
| 3 | Beone Medicines Ltd | 612,622 | 10.48 % |
| 4 | Abbvie Inc | 515,910 | 8.82 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 265 | Foghorn Therapeutics Inc | 132 | 0.00 % |
Market cap and industry share for the rest of Foghorn Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Foghorn Therapeutics Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 260 | Macrogenics Inc | 148 | 60.42 % |
| 261 | Sionna Therapeutics Inc | 148 | -90.64 % |
| 262 | Onkure Therapeutics Inc | 143 | -22.00 % |
| 263 | Atrium Therapeutics Inc | 143 | -88.21 % |
| 264 | Proqr Therapeutics N v | 1,234 | 12.3% |
| 265 | Foghorn Therapeutics Inc | 132 | -52.75 % |
| 266 | Nkarta Inc | 1,234 | 12.3% |
| 267 | Scienture Holdings Inc | 1,234 | 12.3% |
| 268 | Emmis Acquisition Corp | 1,234 | 12.3% |
| 269 | Journey Medical Corp | 1,234 | 12.3% |
| 270 | Zentalis Pharmaceuticals Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Foghorn Therapeutics Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Foghorn Therapeutics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 37.89 % (avg) | -37.9 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -6.23 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 0.14 % | 7.58 % (avg) | -7.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Foghorn Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | - | 15.9x | - |
| P/B | -3.5x | 4.3x | -7.8x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | -25.84 % | -9.83 % (avg) | -16.01 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Foghorn Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2020 | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | 77.63 % | -33.83 % | 36.75 % |
| Operating Margin | - | -7,637.15 % | - | - | - |
| Return on Invested Capital | - | -26.53 % | -49.03 % | -53.79 % | -29.15 % |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Foghorn Therapeutics Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Foghorn Therapeutics Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Foghorn Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 875 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.14 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Foghorn Therapeutics Inc's dedicated Suppliers and Customers pages, not here.
Foghorn Therapeutics Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Foghorn Therapeutics Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Foghorn Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+75.0% annualized vs trailing 12 months).
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (36.40 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Foghorn Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Foghorn Therapeutics Inc | 1.25 | 2.72 | - |
| Abbvie Inc | 0.19 | 0.79 | - |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Hutchmed china Limited | 0.23 | 4.96 | 0.10 |
| Kymera Therapeutics Inc | 3.25 | 10.70 | - |
Sign in to see all peers for Foghorn Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Foghorn Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Foghorn Therapeutics Inc | Q2 2026 | +112.7 % | - |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Hutchmed china Limited | Q4 2025 | -13.0 % | +1,099.2 % |
| Kymera Therapeutics Inc | Q3 2026 | - | - |
| PEERS TOTAL | +10.7 % | +77.7 % |
Sign in to see all peers for Foghorn Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Foghorn Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Foghorn Therapeutics Inc | Q2 2026 | - | +127.3 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Hutchmed china Limited | Q4 2025 | -3.6 % | -44.2 % |
| Kymera Therapeutics Inc | Q3 2026 | - | +74.0 % |
Sign in to see all peers for Foghorn Therapeutics Inc .
Foghorn Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Foghorn Therapeutics Inc | - | - | - |
| Abbvie Inc | 7.48% | 12.87% | - |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Hutchmed china Limited | 26.11% | 30.87% | 36.98% |
| Kymera Therapeutics Inc | - | - | - |
Sign in to see all peers for Foghorn Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Foghorn Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Foghorn Therapeutics Inc | - | 3.60 |
| Abbvie Inc | 50.14 | 7.82 |
| Novartis Ag | 22.73 | 5.61 |
| Amgen Inc | 28.60 | 6.57 |
| Hutchmed china Limited | 29.15 | 24.13 |
| Kymera Therapeutics Inc | - | 125.58 |
| PEERS AVERAGE | 37.60 | 7.07 |
Sign in to see all peers for Foghorn Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.